Why the study?
Does pravastatin improve plasma lipid levels and LDL structure in patients with familial combined hyperlipidemia?
Population
12 patients with familial combined hyperlipidemia (FCHL) documented by studies of first-degree relatives
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
Pravastatin may lower cholesterol in FCHL without normalizing LDL size; leaves open whether particle changes warrant targeted therapies.
Does pravastatin improve plasma lipid levels and LDL structure in patients with familial combined hyperlipidemia?
Pravastatin effectively lowers total and LDL cholesterol in FCHL patients but does not correct the abnormal small, dense LDL particle distribution.
Franceschini et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: